Exatecan hydroxylamine derivative and application thereof

By developing new esatekan derivatives, the problems of toxic side effects and poor cell penetration in tumor treatment have been solved, and effective inhibition and treatment of a variety of cancer cells have been achieved.

CN119080792APending Publication Date: 2024-12-06HANGZHOU ADCORIS BIOPHARMA CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202311192704.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-15
Publication Date
2024-12-06

Smart Images

  • Figure BDA0004451170470000011
    Figure BDA0004451170470000011
  • Figure BDA0004451170470000025
    Figure BDA0004451170470000025
  • Figure BDA0004451170470000031
    Figure BDA0004451170470000031
Patent Text Reader

Abstract

The invention relates to a preparation method of a series of hydroxylamine structure-containing substituted exatecan derivatives and pharmaceutically acceptable salts thereof, and an application of the series of hydroxylamine structure-containing substituted exatecan derivatives and the pharmaceutically acceptable salts thereof in the anti-tumor field. The exatecan derivatives have good tumor cell growth inhibition activity, also have good cell membrane penetrating ability or side killing effect, and can be applied to treatment of tumors in a single drug, a combined drug or as a toxin component of ADC (Analog to Digital Converter).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to exatecan hydroxylamine derivatives and applications thereof. Background Art

[0002] DNA topoisomerase is a kind of essential enzyme widely present in organisms. It affects the topological structure of DNA by regulating supercoiling, linkage, de-linking and nucleic acid dissociation. It is mainly divided into topoisomerase 1 (Top1) and topoisomerase 2 (Topo2). Compared with Top2 inhibitors, Top1 preparations have high efficacy and a wide anti-tumor spectrum, and have become an important target enzyme for designing new anti-tumor drugs. At the same time, the amount of Top1 in various tumor cells such as colon cancer, cervical cancer, and ovarian cancer is much higher than that in normal tissues, and the activity is greatly increased in S-phase tumor cells. Therefore, drugs that inhibit Topo1 can selectively inhibit DNA replication in proliferative tumor cells and have good selectivity.

[0003] Camptothecin enzyme Top1 has inhibitory activity, especially for the complex formed by Top1-DNA. Topoisomerase 1 (Top1) is the main target of camptothecin (CPT) and its analogs. Therefore, camptothecin has significant therapeutic effects on various solid tumors such as gastric cancer, esophageal cancer, lung cancer, bladder cancer, etc., and is a broad-spectrum anti-tumor active drug. Among them, irinotecan, topotecan and belotecan have been approved for the treatment of various cancers in some countries. In addition, DX-8951 and SN38 have been successfully used as payloads of antibody-drug conjugates (ADCs) for targeted treatment of various solid tumors and have achieved significant therapeutic effects and have attracted attention. At present, esatecan has the characteristics of strong toxic side effects, poor cell penetration, and poor stability in the blood system. Summary of the invention

[0004] The present invention provides a series of novel exatecan derivatives, pharmaceutically acceptable salts, stereoisomers or prodrugs thereof, and their use in the field of anti-tumor. These exatecan derivatives have good tumor cell growth inhibition activity, good cell membrane permeability or bystander effect, and can be used for tumor treatment as a single drug, a combination drug or as a toxin component of ADC.

[0005] In one aspect of the present invention, there is provided a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof:

[0006]

[0007] In the formula, R is selected from

[0008] wherein R1 is selected from C1-C6 alkyl, deuterated C1-C6 alkyl or C3-C6 cycloalkyl, wherein the C1-C6 alkyl or C3-C6 cycloalkyl is optionally substituted with one or more halogens;

[0009] Or, R1 is selected from C1-C6 alkyl, wherein two hydrogen atoms on the same carbon atom of the C1-C6 alkyl are simultaneously replaced by -(CH2) j -substituted to form a C3-C6 cycloalkyl group, wherein j is 1, 2, 3, 4 or 5;

[0010] R2 and R3 are each independently selected from hydrogen, C1-C6 alkyl, deuterated C1-C6 alkyl, halogenated C1-C6 alkyl or C3-C6 cycloalkyl,

[0011] X and Y are each independently selected from an O atom or are absent, provided that at least one of X and Y is O;

[0012] m and n are each independently selected from 0, 1, 2 or 3.

[0013] In one embodiment, R1 is selected from C1-C6 alkyl or deuterated C1-C6 alkyl;

[0014] Preferably, R1 is selected from -CH2-, -CD2-, -(CH2)2- or -CH(CH3)-; or,

[0015] R1 is selected from C1-C3 alkyl, wherein two hydrogen atoms on the same carbon atom of the C1-C3 alkyl are simultaneously replaced by -(CH2) j -substituted to form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

[0016] Preferably, R1 is selected from

[0017] In one embodiment, R2 is selected from C1-C6 alkyl or deuterated C1-C6 alkyl;

[0018] Preferably, R2 is selected from methyl, ethyl or deuterated methyl.

[0019] In one embodiment, R3 is selected from hydrogen or C1-C6 alkyl.

[0020] m and n are each independently selected from 0, 1 or 2;

[0021] Preferably, Selected from

[0022] In one embodiment, X is O and Y is absent or Y is O and X is absent.

[0023] In one embodiment, the compound of formula (I) is a compound represented by formula (IIa):

[0024]

[0025] In formula (IIa), R1 and R2 are respectively defined as the compound of formula (I);

[0026] Preferably, R1 is selected from -CH2-, -CD2-, -(CH2)2-, -CH(CH3)- or

[0027] Preferably, R2 is selected from methyl, ethyl or deuterated methyl.

[0028] In one embodiment, the compound of formula (I) is a compound represented by formula (IIb):

[0029]

[0030] In formula (IIb), R1 and R2 are respectively defined as in the compound of formula (I). Preferably, R1 is selected from -CH2-, -CD2-, -(CH2)2-, -CH(CH3)- or

[0031] Preferably, R2 is selected from methyl, ethyl or deuterated methyl.

[0032] In one embodiment, the compound of formula (I) is a compound represented by formula (D1) to (D5):

[0033]

[0034] Another aspect of the present invention provides a method for preparing any of the above compounds, comprising:

[0035] The -2'(S)-amino group of 7,9-cyclohexane in the exatecan structure is reacted with a corresponding compound containing a hydroxylamine structure substitution to prepare an exatecan hydroxylamine derivative;

[0036] in,

[0037] The amino group in the compound containing hydroxylamine structure substitution is protected by amino group protection, and the amino group protection method is to replace the hydrogen on the amino group with an amino protecting group; preferably, the amino protecting group is tert-butyloxycarbonyl;

[0038] The acyl group in the compound substituted with hydroxylamine structure is selected from any one of hydroxylamine substituted acetyl, hydroxylamine substituted propionyl, hydroxylamine substituted cyclobutanecarboxyl, hydroxylamine substituted isoxazolidine-4'-carboxyl, and hydroxylamine substituted deuterated acetyl.

[0039] In one embodiment, the compound containing a hydroxylamine structure is selected from Any one of .

[0040] In one embodiment, the preparation method comprises forming an amide with the -2'(S)-amino group of exatecan 7,9-cyclohexane and the acetyl group substituted with hydroxylamine.

[0041] In one embodiment, the preparation method comprises forming an amide with the -2'(S)-amino group of exatecan 7,9-cyclohexane and the propionyl group substituted with hydroxylamine.

[0042] In one embodiment, the preparation method comprises forming an amide with the -2'(S)-amino group of exatecan 7,9-cyclohexane and a cyclobutanecarboxyl group substituted with hydroxylamine.

[0043] In one embodiment, the preparation method comprises forming an amide with the -2'(S)-amino group of exatecan 7,9-cyclohexane and the isoxazolidine-4'-carboxyl group substituted with hydroxylamine.

[0044] In one embodiment, the preparation method comprises forming an amide with the -2'(S)-amino group of exatecan 7,9-cyclohexane and the deuterated acetyl group substituted with hydroxylamine.

[0045] In another aspect of the present invention, an antibody-drug conjugate is provided, which comprises a small molecule drug, a linker and an antibody, wherein the small molecule drug comprises the above-mentioned compound or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof.

[0046] In another aspect of the present invention, a pharmaceutical composition is provided, which comprises the above-mentioned compound or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof and a pharmaceutically acceptable excipient.

[0047] In another aspect of the present invention, there is provided use of the above-mentioned compound or its pharmaceutically acceptable salt, stereoisomer or prodrug, the antibody-drug conjugate or the pharmaceutical composition in the preparation of a drug for treating cancer.

[0048] In another aspect of the present invention, a method for treating cancer is provided, comprising the step of administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt, stereoisomer or prodrug, antibody-drug conjugate or pharmaceutical composition thereof to a patient in need.

[0049] The above-mentioned compounds or their pharmaceutically acceptable salts, stereoisomers or prodrugs can be used alone, in combination or in the form of antibody-drug conjugates for the treatment of cancer.

[0050] Preferably, the cancer includes any one or more of esophageal adenocarcinoma, gastric cancer, esophageal cancer, lung cancer, lung squamous cell carcinoma, breast cancer, breast adenocarcinoma and bladder cancer cells. DETAILED DESCRIPTION

[0051] I. Definitions

[0052] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the relevant terms and laboratory procedures used herein are terms and conventional procedures widely used in the corresponding fields. At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0053] As used herein and unless otherwise specified, the terms "comprising", "including", "having", "containing", including grammatical equivalents thereof, should generally be understood as open and non-limiting, for example, not excluding other unlisted elements or steps.

[0054] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The stereoisomers include geometric isomers (such as cis, trans structures) and optical isomers (such as enantiomers), and therapeutic substances composed of monomers, racemates, racemic mixtures and pharmaceutically acceptable salts thereof. The compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure form or racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral raw materials or chiral reagents. Racemates, diastereomers, and enantiomers are all included within the scope of the present invention.

[0055] The compounds of the present invention also include tautomeric forms. Tautomeric forms result from the exchange of a single bond with an adjacent double bond accompanied by the migration of a proton.

[0056] As used herein, "pharmaceutically acceptable salts" refer to salts formed between corresponding amine compounds and inorganic or organic acids, or salts formed between corresponding carboxylic acid compounds and alkali metals or alkaline earth metals, or salts formed with organic amines. Inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.; organic acids include, but are not limited to, acetic acid, propionic acid, butyric acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, oxalic acid, succinic acid, lactic acid, citric acid, succinic acid, gluconic acid, maleic acid, fumaric acid, tartaric acid, etc.; alkali metal or alkaline earth metal salts include, but are not limited to, sodium, potassium, calcium, magnesium salts, etc.; organic amine salts include, but are not limited to, salts composed of ammonia, methylamine, ethylamine, propylamine, isopropylamine, dimethylamine, diethylamine, trimethylamine, triethylamine, tert-butylamine, ethylenediamine, ethanolamine, diethanolamine, triethanolamine, morpholine, piperidine, piperazine, amino acids, etc.

[0057] As used herein, "precursor" refers to the form in which the compound is metabolized or undergoes simple chemical changes in the patient's body after the compound enters the human body by an appropriate administration method and is converted into the compound contained in the general formula 1 of the present invention and the corresponding salt. The precursor of the compound includes, but is not limited to, various carboxylic acid esters, carbonate esters, phosphate esters, sulfate esters, sulfonate esters, amino acid esters, gluconate esters, and various amides, acetals, hemiacetals, carbonate amide esters, and the like.

[0058] The numerical ranges herein refer to the individual integers in the given range. For example, "C1-C6" means that the group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms; "C3-C6" means that the group may have 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.

[0059] When any variable (e.g., Rn) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 1-5 Rs, the group may be optionally substituted with up to 5 Rs, and each occurrence of R is an independent choice. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds.

[0060] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 2,2-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups. Methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl are preferred in the present invention.

[0061] The hydrogen atoms described in the present invention can all be replaced by their isotope deuterium.

[0062] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.

[0063] Refers to the chemical bond connection.

[0064] Drug or drug composition

[0065] The medicament or pharmaceutical composition of the present invention can be administered orally, topically, parenterally or mucosally (e.g., buccally, by inhalation or rectally) in a dosage unit formulation containing a conventional non-toxic pharmaceutically acceptable carrier. It is generally desirable to use the oral route. The active agent can be administered orally in the form of capsules, tablets, etc. (see Remington: The Science and Practice of Pharmacy, 20th Edition).

[0066] For oral administration in the form of tablets or capsules, the active drug component can be mixed with non-toxic, pharmaceutically acceptable excipients such as binders (e.g., pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate or dibasic calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica, stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, etc.); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate), coloring and flavoring agents, gelatin, sweeteners, natural and synthetic gums (such as acacia, tragacanth or alginates), buffer salts, carboxymethylcellulose, polyethylene glycol, waxes, and the like. For oral administration in liquid form, the drug component can be combined with a non-toxic, pharmaceutically acceptable inert carrier (e.g., ethanol, glycerol, water), an anti-settling agent (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), an emulsifier (e.g., lecithin or gum arabic), a non-aqueous carrier (e.g., almond oil, oily esters, ethanol or fractionated vegetable oils), a preservative (e.g., methyl or propyl p-hydroxybenzoate or sorbic acid), etc. Stabilizers such as antioxidants (BHA, BHT, propyl citric acid, sodium ascorbate, citric acid) can also be added to stabilize the dosage form.

[0067] Tablets containing the active compound can be coated by methods well known in the art. The composition of the present invention containing the compound of formula I as the active compound can also introduce beads, microspheres or microcapsules, such as those constructed by polyglycolic acid / lactic acid (PGLA). Liquid preparations for oral administration can take the form of solutions, syrups, emulsions or suspensions, for example, or they can be presented as dry products reconstituted with water or other suitable excipients before use. Preparations for oral administration can be suitably formulated to release the active compound in a controlled or delayed manner.

[0068] The term "treating" includes inhibiting, alleviating, preventing or eliminating one or more symptoms or side effects associated with the disease, condition or disorder being treated.

[0069] The term "inhibit" is used relative to a control. One skilled in the art will readily determine the appropriate control for each experiment. For example, a reduced response in a subject or cell treated with a compound is compared to a response in a subject or cell not treated with the compound.

[0070] The term "pharmaceutical composition" means a composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable ingredient selected from the following depending on the mode of administration and the nature of the dosage form, including but not limited to: carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, dispersants, temperature-sensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc.

[0071] The term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a non-toxic drug or medicament that can achieve the desired effect. In embodiments of the present invention, when treating a patient according to the present invention, the amount of a given drug depends on many factors, such as a specific dosing regimen, a disease or condition type and its severity, the uniqueness of the subject or host to be treated (e.g., body weight), but, according to specific surrounding conditions, including, for example, a specific drug, route of administration, condition to be treated, and the subject or host to be treated, the dosage can be routinely determined by methods known in the art. Usually, with respect to the dosage used for adult treatment, the dosage is typically in the range of 0.02-5000 mg / day, such as about 1-1500 mg / day. The desired dosage can be conveniently expressed as a single dose, or a dose administered simultaneously (or in a short period of time) or in a divided dose at appropriate intervals, such as two, three, four, or more divided doses per day. It will be appreciated by those skilled in the art that, although the above-mentioned dosage range is given, the specific effective amount can be appropriately adjusted according to the patient's condition and in conjunction with the physician's diagnosis.

[0072] The term "antibody-drug conjugate" or "antibody-drug conjugate" (ADC) refers to a small molecule drug with biological activity connected to a monoclonal antibody through a chemical link, and the monoclonal antibody acts as a carrier to transport the small molecule drug into the target cells.

[0073] As used herein, the terms "reduce," "inhibit," "mitigate," or "reduce" are used relative to a control. One skilled in the art will readily determine the appropriate control for each experiment. For example, a reduced response in a subject or cell treated with a compound is compared to a response in a subject or cell not treated with the compound.

[0074] Unless otherwise specified, the raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0075] abbreviation

[0076] OE33: human esophageal cancer cells;

[0077] SK-BR-3: human breast cancer cells;

[0078] NCI-N87: human gastric cancer cells;

[0079] NCI-H1975: human lung cancer cells;

[0080] MDA-MB-231: human breast adenocarcinoma cells;

[0081] NCI-H226: human lung squamous cell carcinoma cells;

[0082] TE12: human esophageal cancer cells.

[0083] II. Specific Examples

[0084] In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below. The described embodiments should not be regarded as limiting the present invention. All other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0085] Before further describing the embodiments of the present invention in detail, the nouns and terms involved in the embodiments of the present invention are described. The nouns and terms involved in the embodiments of the present invention are subject to the following interpretations.

[0086] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0087] Example 1: N-(2'O-(N-trideuterated methylamino)oxyacetyl)exatecan (D1)

[0088]

[0089] CD3NO2 (2.24 g, 2.0 mL, 35 mmol) and NH4Cl (1.50 g, 28 mmol) were added to a 100 mL flask containing 35 mL H2O, stirred in an ice-water bath, and then zinc powder (5.7 g, 87.5 mmol) was added proportionally within 1 hour. After stirring for another 2 hours, the mixture was filtered and rinsed with water. The filtrate was acidified to pH = 3 with concentrated HCl (aq) and evaporated to dryness. CD3NHOH was recrystallized from EtOH / Et2O to give D1-1, which was used without further purification.

[0090] At 25°C, in a 250 ml round-bottom flask, D1-1 (4.2 g, 50.29 mmol) was dissolved in THF (100 mL), and Boc anhydride (11.03 g, 50.29 mmol, 11.59 mL) and K2CO3 (6.95 g, 50.29 mmol) were added in sequence. The mixture was stirred magnetically to dissolve most of it. Under nitrogen protection, the mixture was reacted at 25°C for 24 hours. The reaction solution was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to obtain D1-2 (5.36 g, 36.17 mmol, 71.93% yield) as a light yellow liquid.

[0091] At 25°C, in a 250 ml round-bottom flask, D1-2 (1 g, 6.61 mmol) was dissolved in H2O (15 mL), and bromoacetic acid (1.16 g, 8.27 mmol) and NaOH (264.53 mg, 6.61 mmol) were added in sequence, and stirred to dissolve most of them. Under nitrogen protection, the mixture was reacted at 25°C for 24 hours. Ethyl acetate was added to the reaction solution and extracted three times. The mixture was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to obtain D1-3 (1.36 g, 5.52 mmol, 83.54% yield).

[0092] At 0°C, in a 250 mL round-bottom flask, D1-3 (500 mg, 2.44 mmol) was dissolved in DCM (10 mL), and EDCI (467.1 mg, 2.44 mmol) and NHS (280.1 mg, 2.44 mmol) were added in sequence. The mixture was stirred until most of it was dissolved. Under nitrogen protection, the mixture was reacted at 25°C for 3 hours to obtain D1-4.

[0093] At 25°C, in a 25 mL round-bottom flask, exatecan (100 mg, 188.13 μmol) was dissolved in DMF (1 mL), and TEA (30.5 mg, 301.00 μmol) and D1-4 (91 mg, 301.00 μmol) were added in sequence, and stirred to dissolve most of it. Under nitrogen protection, the reaction was carried out at 25°C for 2 hours, and silica gel was added to mix the sample. The sample was passed through a silica gel column (DCM: MeOH = 97:3) and concentrated to obtain a yellow solid D1-5 (85.3 mg, 72.8%); LCMS: [M+1] + 626.21 (calculated: 625.67).

[0094] D1-5 (53 mg, 84.57 μmol) was dissolved in EA (0.5 mL), 4 M HCl / EA (0.5 mL) was added, and stirred to dissolve most of it. Under nitrogen protection, the mixture was reacted at 25 °C for 2 hours, and concentrated to obtain a yellow solid D1 (30.2 mg, 45.80 μmol, yield 54.16%). 1 H NMR (600MHz, DMSO-d6) δ8.53(d,J=8.8Hz,1H),7.81(d,J=10.9Hz,1H),7.31(s,1H),5.66-5.57(m,1H),5.42(s,2H),5.26(s,1H),4.28 (s,2H),3.18(t,J=6.6Hz,2H),2.41(s,3H),2.18(dt,J=36.9,7.2Hz,2H),1.86(ddd,J=21.4,14.2,7.0Hz,2H),0.87(t,J=7.3Hz,3H).

[0095] Example 2: N-(1'-O-(N-methylamino)oxycyclobutane-1'-formyl)exatecan (D2)

[0096]

[0097] In a 10 ml vial, NaOH (555.46 mg, 13.89 mmol), H2O (1 mL), tert-butyl N-hydroxy-N-methyl-carbamate (82.31 mg, 555.50 μmol) were added, and finally 0.5 mL of 1-bromocyclobutanecarboxylic acid (100 mg, 555.50 μmol) was added dropwise to the reaction bottle. The mixture was stirred at 25 °C for 1 h, extracted with DCM, and concentrated to give D2-1 (100 mg, yield 67.98%, 93% HPLC); LCMS: [M+1] +245.83 (calculated: 245.13).

[0098] Exatecan (159.50 mg, 365.44 μmol) was dissolved in DMF (1 mL), and D2-1 (100 mg, 406.04 μmol), EDCI (77.84 mg, 406.04 μmol), NHS (46.73 mg, 406.04 μmol), DCC (83.78 mg, 406.04 μmol) were added in sequence, and stirred at 25 ° C for 2 h. D2-2 (130 mg, 168.45 μmol, yield 41.48%, HPLC 94%) was obtained by purification by silica gel column chromatography; LCMS: [M+1] + 663.27 (calculated: 662.28).

[0099] D2-2 (100 mg, 150.67 μmol) was dissolved in DCM (5 mL), TFA (34.36 mg, 301.34 μmol, 23.06 μL) was added, and the mixture was stirred at room temperature for 1 h. The DCM was concentrated and purified using a C18 Spherical 20-35um 100A 40g reverse column. Acetonitrile and 0.05% TFA aqueous solution were used as B2 and A2 mobile phases, respectively, and HPLC preparation method (254 nm and 214 n wavelength monitoring) was used to obtain D2 (50 mg, 86.94 μmol, yield 57.70%, HPLC 98%). 1 H NMR(600MHz,DMSO-d6)δ8.29(d,J=8.5Hz,1H),7.76(d,J=10.7Hz,1H),7.31(s,1H),5 .57(q,J=7.3,6.9Hz,1H),5.41(s,2H),5.15(s,1H),5.11(s,1H),4.05(s,2H),3.23-3 .07(m,2H),2.71(s,3H),2.38(s,3H),2.16(q,J=6.5Hz,2H),1.86(dtt,J=21.5,14.4, 6.6Hz, 2H), 1.24 (tp, J=12.7, 7.1, 6.4Hz, 2H), 0.88 (q, J=7.4, 6.4Hz, 6H); LCMS: [M+1] + 563.26 (calculated: 562.22).

[0100] Example 3: N-(2'-methyl-2'-O-(N-methylamino)oxyacetyl)exatecan (D3)

[0101]

[0102] Add NaOH (64.94 mg, 1.62 mmol) in H2O (1 mL) to the reaction flask, then add (2S)-2-bromopropanoic acid (100 mg, 649.43 μmol) and tert-butyl N-hydroxy-N-methyl-carbamate (96.23 mg, 649.43 μmol) in sequence, stir at room temperature for 2 h, extract with DCM, and concentrate to obtain product D3-1 (80 mg, 290.59 μmol, yield 44.75%, HPLC 94%) LCMS: [M+1] + 220.23 (calculated: 219.24).

[0103] Exatecan (142.68 mg, 326.91 μmol) was dissolved in DMF (2.04 mL), and TEA (110.27 mg, 1.09 mmol, 151.88 μL), D3-1 (80 mg, 363.24 μmol), EDCI (69.63 mg, 363.24 μmol), and NHS (41.80 mg, 363.24 μmol) were added in sequence. The mixture was stirred at 25 °C for 1 h, extracted with DCM, and purified by silica gel column chromatography to give D3-2 (130 mg, 177.36 μmol, yield 48.83%, HPLC 97%); LCMS: [M+1] + 637.54 (calculated: 636.68).

[0104] D3-2 (90 mg, 141.14 μmol) was dissolved in DCM (5 mL), TFA (2.98 g, 26.14 mmol, 2 mL) was added, and the mixture was stirred at 25 °C for 1 h. Purification was performed using a C18 Spherical 20-35um 100A 40g reverse column, with acetonitrile and 0.05% TFA aqueous solution as B2 and A2 mobile phases, respectively, using an HPLC preparation method (monitored at 254 nm and 214 nm wavelengths) to obtain the product D3 (40 mg, 72.92 μmol, yield 51.67%, HPLC 98%). 1H NMR (600MHz, DMSO-d6) δ8.49(d,J=8.7Hz,1H),7.74(t,J=9.3Hz,1H),7.29(s,1H),6.50(s,1H),5.57(q,J=6.6,6.2Hz,1H) ,5.41(s,2H),5.24(s,0H),5.23-5.14(m,1H),5.12(s,0H),4.39-4.35(m,0H),4.32(q,J=6.8Hz,1H),3.18(td,J=15.7,15. 0,6.8Hz,1H),3.12(s,0H),2.50(s,2H),2.37(s,2H),2.34(d,J=20.3Hz,1H),2.16(q,J=6.3Hz,2H),2.13(s,0H),1.87(td, J=13.9,7.2Hz,2H),1.82(d,J=7.0Hz,0H),1.42(t,J=7.4Hz,1H),1.34(d,J=6.8Hz,2H),0.86(t,J=7.3Hz,3H); LCMS:[M+1] + 537.80 (calculated: 536.56).

[0105] Example 4: N-(2',2'-dideutero-2'-O-(N-trideuteromethylamine)oxyacetyl)exatecan (D4)

[0106]

[0107] At room temperature and under nitrogen protection, exatecan (4 g, 7.77 mmol) and DMF (10 mL) were added to a 50 ml round-bottom flask, stirred and dissolved, 2-bromo-2,2-dideuterio-acetic acid anhydride (2.06 g, 7.77 mmol) and DIEA (1.00 g, 7.77 mmol) were added in sequence, stirred and dissolved, reacted at room temperature for 24 hours, extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to obtain a light yellow solid D4-1 (4.05 g, yield 88.47%); LCMS: [M+1] + 559.37 (calculated: 558.40).

[0108] At room temperature and under nitrogen protection, D4-1 (2 g, 3.58 mmol) was dissolved in DMF (10 mL), and D1-2 (0.753 g, 5.01 mmol) and DBU (0.818 g, 5.37 mmol) were added in sequence. The mixture was mostly dissolved by magnetic stirring, and the reaction was continued overnight under stirring at room temperature. The mixture was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated to obtain a light yellow solid D4-2 (1.05 g, yield 47%); LCMS: [M+1] + 628.58 (calculated: 527.68).

[0109] Under nitrogen protection at 25°C, D4-2 (0.7 g, 1.12 mmol) was dissolved in DCM (10 mL), TFA (1 mL) was added, and the mixture was stirred for 0.5 hours, and concentrated to obtain a light yellow solid D4 (0.536 g, yield 91%); 1 H NMR(500MHz,DMSO-d6)δ8.64(dd,J=8.9,5.5Hz,1H),7.78(dd,J=15.1,10.8Hz,1 H),7.30(d,J=7.8Hz,1H),6.55(s,1H),5.61(dt,J=9.2,4.7Hz,1H),5.42(d,J=4. 0Hz,2H),5.24(d,J=8.5Hz,2H),3.18(t,J=6.4Hz,3H),2.39(d,J=7.9Hz,3H),2. 28-2.10(m,2H),1.86(dp,J=21.4,7.1Hz,2H),0.87(t,J=7.4Hz,3H); LCMS:[M+1] + 528.46 (calculated: 527.56).

[0110] Example 5: N-(isoxazolidine-4'-formyl)exatecan (D5)

[0111]

[0112] Concentrated sulfuric acid (0.5 mL) was added to ethanol (30 mL) of 3-bromo-(2-bromomethyl)propionic acid (3 g, 12.15 mmol), stirred and heated under reflux for 18 h, concentrated, extracted with methyl tert-butyl ether, washed with brine, and concentrated to obtain an oily liquid 3-bromo-(2-bromomethyl)propionic acid ethyl ester, which was directly used in the next reaction without purification.

[0113] N-Boc hydroxylamine (3 g, 22.36 mmol), DMF (10 mL) and 60% NaH (1.79 g, 44.72 mmol) were added to the reaction flask, stirred at 0°C for 10 min, 3-bromo-(2-bromomethyl)propionic acid ethyl ester (6.15 g, 22.36 mmol) was added, the reaction was reacted at room temperature for 3 h, poured into ice water, extracted with methyl tert-butyl ether, and purified by silica gel column chromatography to obtain D5-1 (1.16 g, yield 21%), dissolved in 1:1 THF / H2O (10 mL), LiOH (252.82 mg, 10.56 mmol) was added, stirred at room temperature for 3 h, the reaction solution was concentrated, 1N HCl aqueous solution was added, extracted with DCM, and concentrated to obtain D5-2 (0.9 g, yield 78%).

[0114] D5-3 (1.46 g, 3.35 mmol), D5-2 (0.73 g, 3.35 mmol), DMF (10 mL), EDCI (961.90 mg, 5.02 mmol) and triethylamine (507.74 mg, 5.02 mmol, 699.37 μL) were added to the reaction flask, stirred at room temperature for 3 h, concentrated, and purified by silica gel column chromatography to obtain a white solid product D5-4 (700 mg, yield 19%). The obtained D5-4 was dissolved in a 4M HCl EtOAc solution (5 mL), stirred at room temperature for 3 h, and the reaction solution was concentrated to obtain a white solid product D5 (170 mg, yield 82%); 1 H NMR(500MHz,DMSO-d6)δ7.81(dd,J=11.1,4.2Hz,1H),7.31(d,J=3.5Hz,1H),5.82(dd,J=1 9.1,13.1Hz,1H),5.49-5.31(m,4H),5.16(d,J=14.4Hz,2H),3.74(dt,J=12.5,6.2Hz,1H) ,3.69-3.31(m,5H),3.23(ddd,J=18.3,12.8,5.5Hz,1H),2.85(d,J=14.7Hz,1H),2.37(d, J=5.2Hz,4H),2.22(t,J=13.1Hz,1H),1.87(tt,J=14.4,6.5Hz,3H),0.87(t,J=7.2Hz,3H); 13C NMR (126MHz, DMSO) δ172.85,171.98,171.86,163.20,161.21,157.13,152.91,150.43,148.34,148. 23,145.49,135.92,133.07,129.22,129.11,125.44,125.29,121.25,121.14,120.00,119.62,110. 75,110.57,97.44,72.81,65.80,53.04,52.82,50.93,49.69,49.25,44.71,44.62,40.47,40.30,40 .14,39.97,39.80,39.63,39.47,38.00,37.83,30.92,22.96,22.59,21.74,11.54,8.29.LCMS[M+H] + 535.20 (calculated value 534.19).

[0115] Effect Example 6: Inhibition of tumor cell growth activity

[0116] Tumor cells OE33, SK-BR-3, NCI-N87, NCI-H1975, MDA-MB-231, NCI-H226, and TE1 were cultured in RPMI1640 (Cellmax) containing 10% fetal bovine serum (Cellmax). Tumor cells in the exponential growth phase were diluted to 1×10 5 cells / mL, 100 μL per well was added to a 96-well cell culture plate, and returned to a 37°C, 5% CO2 incubator for overnight culture. The next day, the compound was diluted to 10000nM, 2000nM, 400nM, 80nM, 16nM, 3.2nM, 0.64nM, 0.13nM using culture medium, and the diluted compound was added to a 96-well cell culture plate at 2 μL per well. Three replicates were set for each concentration, and 2 μL of dilution was added to each well of the negative control and blank control groups without adding the compound. After the addition was completed, it was returned to a 37°C, 5% CO2 incubator for further incubation for 72 hours. After the incubation was completed, the cell culture plate was removed, the culture medium in the culture plate was discarded with a pipette, 100 μL of culture medium containing 10% CCK-8 was added to each well, and incubated at 37°C for 3 hours. After the incubation is completed, the culture plate is removed, protected from light, and placed in an ELISA plate. The absorbance is measured at 630 nm as the reference wavelength and 450 nm as the measurement wavelength. Based on the absorbance value, the IC is calculated using the four-parameter regression in GraphPad. 50 Values ​​(Table 1).

[0117] Table 1. IC50 (nM) values ​​of compounds for inhibiting tumor cell growth

[0118]

[0119] "Dxd" is a positive control drug, and its structural formula is

[0120] It can be seen from the results in the table that the exemplary compounds in the examples of the present invention have a good inhibitory effect on the growth of tumor cells, and their active inhibitory IC 50 The values ​​are all below 500nM, or below 100nM or 50nM, and even reach below 10nM.

[0121] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof: In the formula, R is selected from in, R 1 Selected from C 1 ~C 6 Alkyl, deuterated C 1 ~C 6 Alkyl or C 3 ~C 6 Cycloalkyl, wherein the C 1 ~C 6 Alkyl or C 3 ~C 6 Cycloalkyl is optionally substituted with one or more halogens; or, R 1 Selected from C 1 ~C 6 Alkyl, the C 1 ~C 6 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH 2 ) j -substituted to form C 3 ~C 6 Cycloalkyl, wherein j is 1, 2, 3, 4 or 5; R 2 , R 3 are each independently selected from hydrogen, C 1 ~C 6 Alkyl, deuterated C 1 ~C 6 Alkyl, halogenated C 1 ~C 6 Alkyl or C 3 ~C 6 Cycloalkyl, X and Y are each independently selected from an O atom or are absent, provided that at least one of X and Y is O; m and n are each independently selected from 0, 1, 2 or 3.

2. The compound according to claim 1, in, R 1 Selected from C 1 ~C 6 Alkyl or deuterated C 1 ~C 6 alkyl; Preferably, R 1 Selected from -CH 2 -、-CD 2 -、-(CH 2 ) 2 - or -CH(CH 3 )-;or, R 1 Selected from C 1 ~C 3 Alkyl, the C 1 ~C 3 The two hydrogen atoms on the same carbon atom of the alkyl group are simultaneously replaced by -(CH 2 ) j -substituted to form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; Preferably, R 1 Selected from 3. The compound according to claim 1 or 2, in, R 2 Selected from C 1 ~C 6 Alkyl or deuterated C 1 ~C 6 alkyl; Preferably, R 2 Selected from methyl, ethyl or deuterated methyl.

4. The compound according to any one of claims 1 to 3, in, R 3 Selected from hydrogen or C 1 ~C 6 alkyl; m and n are each independently selected from 0, 1 or 2; Preferably, Selected from 5. The compound according to any one of claims 1 to 4, in, X is O and Y does not exist, or Y is O and X does not exist.

6. The compound according to any one of claims 1 to 5, in, The compound of formula (I) is a compound represented by formula (IIa) or formula (IIb): In formula (IIa), R 1 , R 2 Each defines a compound of formula (I); Preferably, R 1 Selected from -CH 2 -、-CD 2 -、-(CH 2 ) 2 -、-CH(CH 3 )-or Preferably, R 2 is selected from methyl, ethyl or deuterated methyl; In formula (IIb), R 1 , R 2 Preferably, R 1 Selected from -CH 2 -、-CD 2 -、-(CH 2 ) 2 -、-CH(CH 3 )-or Preferably, R 2 Selected from methyl, ethyl or deuterated methyl.

7. The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein the compound of formula (I) is a compound represented by formula (D1) to (D5):

8. Antibody-drug conjugates, comprising small molecule drugs, linkers and antibodies, It is characterized in that The small molecule drug comprises the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof.

9. Pharmaceutical compositions, It is characterized in that The invention comprises the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof and a pharmaceutically acceptable excipient or the antibody-drug conjugate according to claim 8.

10. Use of the compound according to any one of claims 1 to 7 or its pharmaceutically acceptable salt, stereoisomer or prodrug, the antibody-drug conjugate according to claim 8 or the pharmaceutical composition according to claim 9 in the preparation of a drug for treating cancer; Preferably, the cancer includes any one or more of esophageal adenocarcinoma, gastric cancer, esophageal cancer, lung cancer, lung squamous cell carcinoma, breast cancer, breast adenocarcinoma and bladder cancer cells.

Citation Information

Cited By

  • Exatecan hydroxylamine derivative and use thereof

    EP4778928A1

  • Exatecan hydroxylamine derivative and use thereof

    WO2025056066A1

  • Fused ring compound, and preparation method therefor and use thereof

    WO2025167722A1